Clinical Trial Update: 24hr Imaging Of HCC After EOVIST [EARLY_Phase 1]

View source ↗

Summary

This is a withdrawal notice for an early-phase trial evaluating 24-hour imaging of hepatocellular carcinoma after EOVIST.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• EOVIST (GADOXETATE DISODIUM)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Hepatocellular Carcinoma | EARLY_Phase 1 | Status: WITHDRAWN